During Walmsley’s near eight-year tenure, GSK shares have delivered a total annualized return of about 3%, compared with more than 7% for peers, according to data compiled by Bloomberg. GSK has ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...